Weekly Paclitaxel in Elderly Patients with Advanced Breast Cancer

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Drugs in R&D

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.2165/00126839-200405010-00002PMID 14725485
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study.

  2002cited by this paper
• Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer.

  2001cited by this paper
• Epidemiology of Breast Cancer in Older Women

  2001cited by this paper
• Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial.

  2001cited by this paper
• BREAST CANCER AND AGING: Clinical Interactions

  2000cited by this paper
• Biomarkers and outcome after tamoxifen treatment in node-positive breast cancers from elderly women

  2000cited by this paper
• Paclitaxel in advanced non-small cell lung cancer : an alternative high-dose weekly schedule.

  2000cited by this paper
• One-hour paclitaxel via weekly infusion: dose-density with enhanced therapeutic index.

  1998cited by this paper
• Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.

  1998cited by this paper
• Weekly high-dose paclitaxel in metastatic and locally advanced breast cancer: a preliminary report.

  1997cited by this paper
• Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer.

  1997cited by this paper
• Dose-escalation study of weekly 1-hour paclitaxel administration in patients with refractory cancer.

  1997cited by this paper
• Phase I study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer.

  1996cited by this paper
• A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines.

  1996cited by this paper
• Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer.

  1996cited by this paper
• Single-agent paclitaxel as first-line treatment of metastatic breast cancer: the British experience.

  1996cited by this paper
• Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer.

  1995cited by this paper
• Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response.

  1995cited by this paper
• Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial.

  1995cited by this paper
• Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.

  1995cited by this paper
• Taxol: a novel investigational antimicrotubule agent.

  1990cited by this paper

• Chemotherapy treatment for older women with metastatic breast cancer: what is the evidence?

  2011cites this paper
• Impact of the Physiological Effects of Aging on the Pharmacokinetics and Pharmacodynamics of Systemic Breast Cancer Treatment

  2010cites this paper
• Effects of sustained and intermittent paclitaxel therapy on tumor repopulation in ovarian cancer

  2008cites this paper
• Cytotoxic therapy for the elderly with metastatic breast cancer: a review on safety, pharmacokinetics and efficacy.

  2007cites this paper
• Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762).

  2006cites this paper
• Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer).

  2005cites this paper